329 related articles for article (PubMed ID: 21387286)
21. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
Barok M; Isola J; Pályi-Krekk Z; Nagy P; Juhász I; Vereb G; Kauraniemi P; Kapanen A; Tanner M; Vereb G; Szöllösi J
Mol Cancer Ther; 2007 Jul; 6(7):2065-72. PubMed ID: 17620435
[TBL] [Abstract][Full Text] [Related]
22. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
[TBL] [Abstract][Full Text] [Related]
23. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.
Kono K; Takahashi A; Ichihara F; Sugai H; Fujii H; Matsumoto Y
Cancer Res; 2002 Oct; 62(20):5813-7. PubMed ID: 12384543
[TBL] [Abstract][Full Text] [Related]
24. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
[TBL] [Abstract][Full Text] [Related]
25. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.
Barok M; Balázs M; Nagy P; Rákosy Z; Treszl A; Tóth E; Juhász I; Park JW; Isola J; Vereb G; Szöllosi J
Cancer Lett; 2008 Feb; 260(1-2):198-208. PubMed ID: 18096313
[TBL] [Abstract][Full Text] [Related]
26. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
[TBL] [Abstract][Full Text] [Related]
27. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
[TBL] [Abstract][Full Text] [Related]
28. Precision glycocalyx editing as a strategy for cancer immunotherapy.
Xiao H; Woods EC; Vukojicic P; Bertozzi CR
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10304-9. PubMed ID: 27551071
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme.
Kawaguchi Y; Kono K; Mizukami Y; Mimura K; Fujii H
Anticancer Res; 2009 Jun; 29(6):2137-46. PubMed ID: 19528474
[TBL] [Abstract][Full Text] [Related]
30. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients.
Suzuki E; Kataoka TR; Hirata M; Kawaguchi K; Nishie M; Haga H; Toi M
BMC Cancer; 2015 Feb; 15():39. PubMed ID: 25655677
[TBL] [Abstract][Full Text] [Related]
31. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
Barok M; Tanner M; Köninki K; Isola J
Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
[TBL] [Abstract][Full Text] [Related]
33. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
Roberti MP; Rocca YS; Amat M; Pampena MB; Loza J; Coló F; Fabiano V; Loza CM; Arriaga JM; Bianchini M; Barrio MM; Bravo AI; Domenichini E; Chacón R; Mordoh J; Levy EM
Breast Cancer Res Treat; 2012 Dec; 136(3):659-71. PubMed ID: 23065032
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
35. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.
Kohrt HE; Houot R; Weiskopf K; Goldstein MJ; Scheeren F; Czerwinski D; Colevas AD; Weng WK; Clarke MF; Carlson RW; Stockdale FE; Mollick JA; Chen L; Levy R
J Clin Invest; 2012 Mar; 122(3):1066-75. PubMed ID: 22326955
[TBL] [Abstract][Full Text] [Related]
36. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
37. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients.
Beano A; Signorino E; Evangelista A; Brusa D; Mistrangelo M; Polimeni MA; Spadi R; Donadio M; Ciuffreda L; Matera L
J Transl Med; 2008 May; 6():25. PubMed ID: 18485193
[TBL] [Abstract][Full Text] [Related]
38. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells.
Verneris MR; Arshi A; Edinger M; Kornacker M; Natkunam Y; Karimi M; Cao YA; Marina N; Contag CH; Negrin RS
Clin Cancer Res; 2005 Jun; 11(12):4561-70. PubMed ID: 15958642
[TBL] [Abstract][Full Text] [Related]
39. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
